SecBot SecBot

TLX drug pipeline

Telix Pharmaceuticals Ltd · 5 rated drugs
$8.92
−3.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.1%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
5
1 bullish · 1 mixed · 3 neutral
Phase 3 trials
1
0 with results posted

Upcoming catalysts

1 dated
  1. Jan 2027
    68Ga-PSMA-11
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3 (completed)
Time to marketUnknown — Phase 3 is complete but no regulatory submission has been announced. If filed after the merger closes (late 2026/early 2027), potential approval could be 12-24 months post-filing.

ITM-11 177Lu-edotreotide Updated Oct 24

What to watch

Monitor the Telix shareholder vote on December 1, 2026 for the ITM merger, approval is the key near-term catalyst for ITM-11's path forward. Post-merger, watch for regulatory submission plans for ITM-11 in GEP-NETs, which would compete with Novartis' Lutathera. The elevated short volume (~63% weighted ratio) suggests significant bearish positioning that could amplify a positive vote outcome.

Bull case
  • ITM-11 has completed Phase 3 development, de-risking the asset significantly compared to earlier-stage pipeline programs. The COMPETE trial data provides a foundation for regulatory filings.
  • The ITM merger gives Telix vertical integration with commercial-scale lutetium-177 production capabilities, a key competitive advantage in the radiopharmaceutical space where isotope supply is a bottleneck.
  • Telix has a strong commercial track record (Q3 2026 revenue $245M, +19% YoY) and a proven ability to gain FDA approvals (Pixclara for glioma, Illuccix/Gozellix for prostate cancer), providing a commercial infrastructure to launch ITM-11.
Bear case
  • ITM-11 would compete directly with Novartis' Lutathera (177Lu-dotatate), which is already approved and established as the standard-of-care PRRT for GEP-NETs, creating a significant commercial adoption hurdle.
  • The ITM merger ($1.65B upfront + $700M milestones) introduces integration risk and potential shareholder dilution, ITM shareholders will own 23.7% of the combined entity.
  • Elevated short volume (~63% weighted short-volume ratio over 28 sessions) indicates significant bearish positioning, suggesting skepticism about the merger value or ITM-11's competitive positioning.
● neutral
Impact
PhasePhase 3
Time to marketLikely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)

TLX591-Tx lutetium (177Lu) rosopatamab tetraxetan Updated Jul 1

What to watch

Watch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.

Bull case
  • Antibody-based approach is differentiated from Pluvicto: prolonged tumor retention, higher specificity, and a short two-dose regimen could offer meaningful clinical and convenience advantages.
  • Telix estimates TLX591-Tx manufacturing cost could be ~20% of Pluvicto's cost, which would create significant pricing/access advantages if approved.
  • Phase 3 Part 1 met all primary safety/dosimetry objectives with no new safety signals, de-risking the therapeutic before the larger Part 2 readout.
Bear case
  • Novartis' Pluvicto is already approved and on the market for PSMA-positive mCRPC, TLX591-Tx must prove superiority or at least non-inferiority with a meaningful differentiating advantage to capture share.
  • Part 2 of the Phase 3 trial is an event-driven rPFS readout with ~490 patients, readout likely 2+ years away, no near-term binary catalyst to drive the stock.
  • TLX591-Tx uses an antibody approach that is inherently more complex to manufacture and with different pharmacokinetics than small molecules, regulatory and CMC risks are not yet de-risked.
● neutral
Impact
PhasePhase 3 (ZIRCON) completed; BLA under FDA review
Time to marketBLA for ccRCC under FDA review per Telix's May 2026 release; US commercialization would follow an FDA decision whose date is not confirmed in available data (potentially within ~12 months of approval).

Zircaix zirconium Zr 89 girentuximab Updated Aug 20

What to watch

Watch for (1) an FDA action/PDUFA announcement on the Zircaix BLA in ccRCC, the single biggest binary for this drug, undated in available data, and (2) the September 22, 2026 R&D Day, where Telix may update Zircaix launch/regulatory timing.

Bull case
  • Phase 3 ZIRCON data (published May 2026 in European Urology) show Zircaix PET/CT highly predictive of renal malignancy across all subtypes, not just ccRCC, with a 98% positive predictive value, a strong efficacy narrative if the FDA follows. (GlobeNewswire Zircaix release)
  • Commercial platform is firing: H1 2026 revenue of $477M (+22% YoY) and net profit of $38M vs a $2M loss a year earlier, with FY26 revenue guidance at the upper end of $950M-$970M and total revenue/other income guided above $1B. (Telix H1 2026 results release)
  • Same-target franchise synergies: the therapeutic sibling TLX250-Tx (177Lu-girentuximab) just entered Phase 3 LUTEON for ccRCC, extending the CAIX platform beyond imaging. (LUTEON release)
Bear case
  • Imaging agents are typically lower-revenue, reimbursement-sensitive products; Telix's own GOZELLIX FDA approval (March 2025) moved TLX only ~+1.1% in one day / +4.3% in five, suggesting approval alone may not be a huge share-price catalyst.
  • The exploratory multi-subtype analysis is NOT part of the pending BLA, so the near-term label is narrower (ccRCC) and label-expansion is a later event. (Telix press summary)
  • Dilution overhang: H1 2026 results disclosed an ATM facility for potential equity issuance, alongside a $600M convertible bond refinancing and raised R&D guidance of $230-270M. (H1/Q2 2026 press summaries)
▲ bullish
Impact
PhaseApproved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
Time to marketAlready marketed — FDA approved March 21, 2025; US commercial launch announced June 2025

Gozellix gallium ga 68 gozetotide Updated Aug 20

What to watch

Gozellix is an already-approved, launched product, so there is no approval binary left to trade, the investor angle is commercial execution. Watch Telix's quarterly revenue disclosures (FY2026 guidance of ~US$950-970M plus US$40M Regeneron other income, Q2 2026 reported Aug 20, 2026) and any market-share data vs. Lantheus' PYLARIFY and Telix's own Illuccix, since Gozellix partly cannibalizes its sibling product. Bigger single-stock moves in TLX over the next year are more likely to come from the therapy pipeline (ProstACT Phase 3) than from this imaging agent.

Bull case
  • Already FDA-approved (March 21, 2025, NDA 219592) and commercially launched in the US by June 2025, the regulatory risk is gone (FDA approval letter; Urology Times launch story).
  • Proven revenue contribution: Telix met upgraded FY2025 guidance of ~US$804M with Q4 2025 up 46% YoY driven in part by the Gozellix launch after CMS reimbursement, and H1 2026 group revenue reached US$477M (+22% YoY) with Precision Medicine revenue +27% YoY and 65% gross margin.
  • Two-product strategy (Illuccix + Gozellix) is gaining market share, per management commentary in the FY2025 and H1 2026 releases, with the kit format expanding access beyond Illuccix's supply model.
Bear case
  • No pending regulatory binary: the approval catalyst has passed, so Gozellix alone cannot drive a big dated share-price move, future TLX moves hinge on other pipeline readouts (e.g., ProstACT therapy trial) rather than this diagnostic.
  • Competitive and cannibalization risk: PSMA-PET imaging faces Lantheus' PYLARIFY, and Gozellix competes with Telix's own Illuccix (same radioactive tracer molecule), so incremental revenue is partly a transfer between the company's two products rather than pure new demand.
  • Diagnostic economics are modest versus therapeutics, imaging agents earn per-dose revenue, and Telix still posted a ~US$7.1M net loss in FY2025 after heavy R&D spend and the RLS Radiopharmacies acquisition, with a new shelf registration raising dilution potential.
● neutral
Impact
PhasePhase 3 (pivotal, just initiated); Phase 1 safety stage complete
Time to marketUnknown — likely several years. Phase 3 (IPAX BrIGHT) began dosing in April 2026; no primary-completion or readout date has been disclosed, so approval (if trials succeed) is not expected before ~2030.

TLX101-Tx iodofalan (131I-iodofalan) Updated Aug 20

What to watch

TLX101-Tx itself has no near-term stock catalyst, the Phase 3 IPAX BrIGHT trial (recurrent glioblastoma) just began enrolling, so the next meaningful events are enrollment/timeline updates, likely at Telix's R&D Day on September 22, 2026. Investors holding TLX should treat TLX101-Tx as a long-dated pipeline option; near-term share-price drivers are the commercial business (H1 2026 revenue $477M) and the September 11, 2026 PDUFA for the separate diagnostic TLX101-Px (Pixclara), not this therapy.

Bull case
  • First-mover status: Telix says TLX101-Tx is the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, a disease with a huge unmet need (per April 2026 first-patient-dosed release).
  • Phase 1 de-risking: IPAX-2 completed enrollment in May 2026 with no dose-limiting toxicities observed at any dose, including the maximum 2 x 5 GBq (10 GBq total), a positive safety signal ahead of the pivotal trial.
  • Theranostic franchise: pairs with Telix's brain-tumor imaging candidate (TLX101-Px/FET PET) and a June 2026 neuro-oncology webinar signals a deliberate GBM franchise build, not a one-off program.
Bear case
  • No near-term catalyst: the pivotal Phase 3 only started enrolling in April 2026 and efficacy results are years away, a long, unresolved binary with no dated readout in the next ~12 months.
  • GBM is a graveyard indication: recurrent glioblastoma has seen many late-stage failures; the efficacy bar (overall survival) is high and the recurrent setting is especially hard.
  • Small slice of a big company: TLX101-Tx is one of several therapy programs (TLX591-Tx prostate, TLX250-Tx renal, TLX597-Tx) at a company already driven by commercial products, even clean Phase 1 news (May 2026) was assessed as only a modest stock driver.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Mar 20, 2025GozellixApproval+1.1%−0.5%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
68Ga-PSMA-11PSMA PET Combined With MRI for the Detection of PCaPhase 3Active not recruiting338Jan 2027